Medicare Coverage Issues Manual
Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of AutoimmuneMucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) BullousPemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5)Epidermolysis Bullosa Acquisita.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: May 01, 2002
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.